Latest International AIDS Vaccine Initiative Stories
Research conducted at Oregon Health & Science University's Vaccine and Gene Therapy Institute (VGTI) has developed a vaccine candidate in non-human primates that may eventually lead to a vaccine against Human Immunodeficiency Virus (HIV).
ATLANTA, May 4, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTCBB: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, today released its 2010 Annual Report and President's Letter to the Company's stockholders.
ATLANTA, April 27, 2011 /PRNewswire/ -- GeoVax Labs, Inc.
ATLANTA, April 7, 2011 /PRNewswire/ -- Harriet Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc.
ATLANTA, Feb. 9, 2011 /PRNewswire/ -- GeoVax Labs, Inc.
LOS ANGELES, Feb. 7, 2011 /PRNewswire/ -- The Black AIDS Institute ("BAI"), the only national HIV/AIDS think tank focused exclusively on the Black community in the US, today released its 2011 State of AIDS in Black America report, Deciding Moment.
ATLANTA, Jan. 20, 2011 /PRNewswire/ -- Harriet L. Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc.
SINGAPORE, Dec. 8, 2010 /PRNewswire-Asia/ -- From the 1st to the 3rd of March 2011, vaccine leaders from developing and developed world will meet at Vaccine World Summit in New Delhi.
ATLANTA, Dec. 6, 2010 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), has appointed David A.
ATLANTA, Nov. 29, 2010 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc.
- A hairdresser.